{"url_path":"/sec/grce/8-k/2026-04-27/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Events.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-04-27","source_url":"https://www.sec.gov/Archives/edgar/data/1444192/0001140361-26-016834-index.html","accession_number":"0001140361-26-016834","cik":"0001444192","ticker":"GRCE","issuer_name":"Grace Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1444192/0001140361-26-016834-index.html","primary_entity_key":"0001444192","primary_entity_name":"Grace Therapeutics, Inc."},"word_count":45,"has_tables":true,"body_markdown":"Item 8.01.\n\nOther Events.\n\nOn April 27, 2026, Grace Therapeutics, Inc. (the “Company”) updated\nits corporate presentation. A copy of the updated corporate presentation is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 8.01."}